<SEC-DOCUMENT>0001193125-23-007185.txt : 20230112
<SEC-HEADER>0001193125-23-007185.hdr.sgml : 20230112
<ACCEPTANCE-DATETIME>20230112160613
ACCESSION NUMBER:		0001193125-23-007185
CONFORMED SUBMISSION TYPE:	424B7
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230112
DATE AS OF CHANGE:		20230112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACHIEVE LIFE SCIENCES, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B7
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269059
		FILM NUMBER:		23526001

	BUSINESS ADDRESS:	
		STREET 1:		22722 29TH DR. SE
		STREET 2:		SUITE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		425-686-1500

	MAIL ADDRESS:	
		STREET 1:		22722 29TH DR. SE
		STREET 2:		SUITE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ONCOGENEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B7
<SEQUENCE>1
<FILENAME>d420468d424b7.htm
<DESCRIPTION>424B7
<TEXT>
<HTML><HEAD>
<TITLE>424B7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:71%; font-size:10pt; font-family:Times New Roman"><B>Filed pursuant to Rule 424(b)(7) <BR>Registration Statement No. 333-269059 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g420468g01a03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>12,279,423 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the registration for potential offer and sale from time to time of up to 12,279,423 shares of our common stock, par value $0.001
per share (the &#147;Shares&#148;), by the selling stockholders identified in the &#147;Selling Stockholders&#148; section of this prospectus.&nbsp;The Shares registered hereunder consist of (i) 8,186,282 outstanding shares held by certain of the
selling stockholders and (ii) 4,093,141 shares issuable to certain of the selling stockholders upon exercise of certain outstanding common stock purchase warrants held by such selling stockholders (the &#147;Warrants&#148;). For more information
regarding the Shares, see &#147;Selling Stockholders&#148; herein.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell the Shares directly to purchasers or through
underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions. The selling stockholders may sell the Shares at any time at market prices prevailing at the time of sale or at privately
negotiated prices. For more information regarding the selling stockholders and the sale of the Shares, see &#147;Selling Stockholders&#148; and &#147;Plan of Distribution&#148; herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the Shares by the selling
stockholders.&nbsp;This prospectus also relates to the issuance by us of the shares of common stock issuable upon the exercise of Warrants. We will receive proceeds from any exercise of the Warrants for cash. We will pay the expenses incurred in
registering the Shares, including legal and accounting fees. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Capital Market under the symbol
&#147;ACHV.&#148; On January&nbsp;9, 2023 the last reported sales price for our common stock was $2.80 per share. None of the other securities we may offer are currently traded on any securities exchange. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. Before making any investment in these securities, you should consider carefully the risks and
uncertainties in the section entitled &#147;<A HREF="#toc420468_3">Risk&nbsp;Factors</A>&#148; beginning on page&nbsp;5 of this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is January&nbsp;9, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_4">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_5">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_6">INCORPORATION OF INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_9">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc420468_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the United States
Securities and Exchange Commission (the &#147;SEC&#148;). Under this registration process, the selling stockholders may, from time to time, sell or otherwise distribute the securities offered by them as described in the section titled &#147;Plan of
Distribution&#148; in this prospectus. We will not receive any proceeds from the sale by such selling stockholders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of
common stock issuable upon the exercise of Warrants. We will receive proceeds from any exercise of the Warrants for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, the
selling stockholders, nor any agent, underwriter or dealer have authorized anyone to give you any information or to make any representation other than the information and representations contained in or incorporated by reference into this prospectus
or any applicable prospectus supplement. We, the selling stockholders and any agent, underwriter or dealer take no responsibility for, and can provide no assurance as to the reliability of, any other information others may give you.&nbsp;You may not
imply from the delivery of this prospectus and any applicable prospectus supplement, nor from a sale made under this prospectus and any applicable prospectus supplement, that our affairs are unchanged since the date of this prospectus and any
applicable prospectus supplement or that the information contained in any document incorporated by reference is accurate as of any date other than the date of the document incorporated by reference, regardless of the time of delivery of this
prospectus and any applicable prospectus supplement or any sale of a security. This prospectus and any applicable prospectus supplement may only be used where it is legal to sell the securities. We urge you to read carefully this prospectus (as
supplemented and amended), together with the information incorporated herein by reference as described under the heading &#147;Incorporation of Information by Reference&#148; before deciding whether to invest in any of the shares of common stock
being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but
reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be
incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, unless the context otherwise requires, the terms &#147;Achieve,&#148; the &#147;Company,&#148; &#147;we,&#148;
&#147;us,&#148; and &#147;our&#148; refer to Achieve Life Sciences, Inc. together with its subsidiaries, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained in other parts of this prospectus or incorporated by reference in this prospectus from our
Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2021, and our other filings with the SEC listed below under the heading &#147;Incorporation of Information by Reference.&#148; This
summary may not contain all the information that you should consider before investing in securities. You should read the entire prospectus and the information incorporated by reference in this prospectus carefully, including &#147;Risk Factors&#148;
and the financial data and related notes and other information incorporated by reference, before making an investment decision. See &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage pharmaceutical
company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction. Our primary focus is to address the global smoking and nicotine addiction epidemic, which is a leading cause of
preventable disease and death and is responsible for more than eight million deaths annually worldwide. We also plan to expand our focus to address other methods of nicotine addiction such as
<FONT STYLE="white-space:nowrap">e-cigarettes/vaping.</FONT> Our management team has significant experience in growing emerging companies focused on the development of under-utilized pharmaceutical compounds to meet unmet medical needs. We intend to
use this experience to develop and ultimately commercialize cytisinicline either directly or via strategic collaborations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in California in October 1991 and subsequently reorganized as a Delaware corporation in March 1995. Our principal executive
offices are located at 1040 West Georgia Street, Suite 1030, Vancouver, B.C. V6E 4H1, and our telephone number is (604) <FONT STYLE="white-space:nowrap">210-2217.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2022, we entered into
subscription agreements with certain accredited investors, pursuant to which we agreed to sell and issue, in a private placement transaction, 4,093,141 units at a purchase price of $4.625 per unit, with each unit consisting of two shares of common
stock and a common stock purchase warrant to purchase one share of common stock (the &#147;Warrants&#148;). The Warrants are exercisable at a price per share of common stock of $4.50, subject to adjustment. The Warrants are exercisable beginning on
the six month anniversary of the initial closing date of the private placement offering, or May&nbsp;18, 2023 (the &#147;Initial Exercise Date&#148;), and will expire on the seven year anniversary of the initial closing date of the private placement
offering, or November&nbsp;18, 2029. The Warrants cannot be exercised by a Warrant holder if, after giving effect thereto, such Warrant holder would beneficially own more than 19.99% of our outstanding common stock. Additionally, subject to certain
exceptions, if, after the Initial Exercise Date, (i)&nbsp;the volume weighted average price of our common stock for each of 30 consecutive trading days (the &#147;Measurement Period&#148;), which Measurement Period commenced on November&nbsp;18,
2022, exceeds 300% of the exercise price (subject to adjustments for stock splits, recapitalizations, stock dividends and similar transactions), (ii)&nbsp;the average daily trading volume for such Measurement Period exceeds $500,000 per trading day
and (iii)&nbsp;certain other equity conditions are met, and subject to a beneficial ownership limitation, then we may call for cancellation of all or any portion of the Warrants then outstanding. We received approximately $17.9&nbsp;million in net
proceeds from the private placement after deducting placement agent expenses and commissions and offering expenses payable by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection
with our entry in the subscription agreements, we granted to the participating accredited investors certain registration rights with respect to the shares of common stock issued in the offering and the shares of
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock underlying the Warrants pursuant to a registration rights agreement dated November&nbsp;18, 2022. We are registering the securities offered hereby pursuant to such registration
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we have filed with the SEC to register 12,279,423 shares of our common stock acquired in
the private placements (the &#147;Shares&#148;). The shares of common stock registered hereunder consist of (i)&nbsp;outstanding shares of common stock held by the selling stockholders that were purchased in the private placement and
(ii)&nbsp;shares issuable upon exercise of the Warrants issued in the private placements. The Shares are being registered for resale or other disposition by the selling stockholders. We will not receive any proceeds from the sale or other
disposition of the Shares registered hereunder, or interests therein. This prospectus also relates to the issuance by us of the shares of common stock issuable upon the exercise of Warrants. We will receive proceeds from any exercise of the Warrants
for cash. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by selling stockholders </P></TD>
<TD>12,279,423 shares, which includes (i) 8,186,282 shares of common stock held by the selling stockholders and (ii) 4,093,141 shares of common stock issuable upon the exercise of the Warrants held by the selling stockholders identified in the
&#147;Selling Stockholders&#148; section of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus. This prospectus also relates to the issuance by us of the shares of common stock issuable upon the exercise of Warrants. We will receive
proceeds from any exercise of the Warrants for cash. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;Risk Factors included herein, for a discussion of factors you should carefully consider before deciding to invest in our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Capital Market Symbol </P></TD>
<TD>ACHV. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders named in this prospectus may offer and sell up to an aggregate of 12,279,423 shares of our common stock,
which includes (i) 8,186,282 shares of common stock held by the selling stockholders and (ii)&nbsp;4,093,141 shares of common stock issuable upon the exercise of the Warrants held by the selling stockholders. Throughout this prospectus, when we
refer to the shares of our common stock being registered on behalf of the selling stockholders, we are referring to all 12,279,423 shares of common stock, including 4,093,141 shares of common stock that become issuable upon the exercise of the
Warrants held by the selling stockholders as of May&nbsp;18, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We agreed to file this prospectus pursuant to a registration rights agreement with the
selling stockholders, dated November&nbsp;18, 2022 (the &#147;Registration Rights Agreement&#148;). Additional information with respect to the Registration Rights Agreement is contained in this prospectus under the heading &#147;Selling
Stockholders&#148; and in our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission on November&nbsp;18, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to the selling stockholders, we are referring to the selling stockholders identified in the &#147;Selling Stockholders&#148; section of this
prospectus and, as applicable, any donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares received after the date of this prospectus from a selling
stockholder as a gift, pledge, or other <FONT STYLE="white-space:nowrap">non-sale</FONT> related transfer that may be identified in a supplement to this prospectus or, if required, a post-effective amendment to the registration statement of which
this prospectus is a part. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of securities will
contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#147;Risk Factors&#148; in
the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus, including in our Quarterly Report on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September&nbsp;30, 2022, and other documents we file with the SEC that are deemed incorporated by reference into this prospectus, which may be amended, supplemented, or
superseded from time to time by other reports we file with the SEC in the future The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem
immaterial may also affect our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains or incorporates by reference &#147;forward-looking statements&#148; within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ
materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. Such statements include, but are not limited to, statements about future financial and operating results, plans,
objectives, expectations and intentions, costs and expenses, interest rates, outcome of contingencies, financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management and other statements that are
not historical facts. You can find many of these statements by looking for words like &#147;believes,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;estimates,&#148; &#147;may,&#148; &#147;should,&#148; &#147;will,&#148;
&#147;could,&#148; &#147;plan,&#148; &#147;intend&#148; or similar expressions in this prospectus or in documents incorporated by reference into this prospectus. We intend that such forward-looking statements be subject to the safe harbors created
thereby. Examples of these forward-looking statements include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">progress and preliminary and future results of any clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anticipated regulatory filings, requirements and future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the impact of the macroeconomic and geopolitical environment, including inflation,
pandemics and geopolitical conflict, and their potentially material adverse impact on our business and the execution of our preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance of, and our ability to obtain sufficient supply of cytisinicline in a timely manner from,
third-party suppliers and manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing and plans for the expansion of our focus to address other methods of nicotine addiction;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing and amount of future contractual payments, product revenue and operating expenses; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market acceptance of our products and the estimated potential size of these markets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on the current beliefs and expectations of our management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results may differ materially from current expectations and projections. Factors that might cause such a difference include the risk
factors identified under the caption &#147;Risk Factors&#148; in this prospectus, as well as those identified under Part II, Item 1A. &#147;Risk Factors&#148; in our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the
quarter ended September&nbsp;30, 2022, filed with the SEC on November&nbsp;14, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this prospectus or, in the case of documents referred to or incorporated by reference, the date of those documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in
their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this
prospectus or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional
updates with respect to those or other forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_5"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;under</FONT> the Securities Act
with respect to the securities offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, the exhibits filed therewith or the documents
incorporated by reference therein. For further information about us and the securities offered hereby, reference is made to the registration statement, the exhibits filed therewith and the documents incorporated by reference therein. Statements
contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance, we refer you to the copy of such contract or
other document filed as an exhibit to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and are required to file annual, quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains an Internet site (http://www.sec.gov) that contains
reports, proxy and information statements, and various other information about us. You may also inspect the documents described herein at our principal executive offices, 1040 West Georgia Street, Suite 1030, Vancouver, B.C. V6E&nbsp;4H1, during
normal business hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about us is also available at our website at https://achievelifesciences.com/. However, the
information on our website is not a part of this prospectus and is not incorporated by reference into this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_6"></A>INCORPORATION OF INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information that we file with the SEC, which means that we can disclose important
information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede this information. A
Current Report (or portion thereof) furnished, but not filed, on Form <FONT STYLE="white-space:nowrap">8-K</FONT> shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future
filings we make with the SEC under Section&nbsp;13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/949858/000156459022009485/achv-10k_20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;10, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended
March&nbsp;31, 2022, filed with the SEC on<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/949858/000156459022019876/achv-10q_20220331.htm"> May<U></U>&nbsp;12, 2022</A>; June&nbsp;
30, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/949858/000156459022029122/achv-10q_20220630.htm">August<U></U>&nbsp;11, 2022</A>; and September&nbsp;
30, 2022, filed with the SEC on<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/949858/000156459022037646/achv-10q_20220930.htm"> November&nbsp;14, 2022</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/949858/000156459022010148/achv-8k_20220308.htm">March&nbsp;15,
 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/949858/000156459022015873/achv-8k_20220426.htm">April<U></U>&nbsp;
27, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/949858/000156459022022030/achv-8k_20220531.htm">June<U></U>&nbsp;
1, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/949858/000156459022038025/achv-8k_20221114.htm">November<U></U>&nbsp;
18, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/949858/000156459022038292/achv-8k_20221122.htm">November<U></U>&nbsp;25, 2022</A> (excluding any information furnished in such report under Item
2.02); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on Form <FONT
STYLE="white-space:nowrap">8-A</FONT> filed with the SEC on September&nbsp;27, 1995 (paper filing) under Section&nbsp;12 of the Exchange Act, including any amendment or report filed for the purpose of updating such description; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement,
of which this prospectus is a part, and prior to the effectiveness of the registration statement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish
without charge to you, on written or oral request, a copy of any or all of such documents that has been incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the
documents that this prospectus incorporates). You may request a copy of these filings (other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing) at no cost by writing, telephoning or <FONT
STYLE="white-space:nowrap">e-mailing</FONT> us at the following address, telephone number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Achieve Life Sciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1040
West Georgia Street, Suite 1030 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Vancouver, BC V6E 4H1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tel: (604) <FONT STYLE="white-space:nowrap">210-2217</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Sandra Thomson </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of
these filings are also available through the &#147;Investors&#148; section of our website at www.achievelifesciences.com. See the section of this prospectus entitled &#147;Where You Can Find More Information&#148; for information concerning how to
obtain copies of materials that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus, or in a document, all or a portion of
which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or
supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proceeds from the sale of the Shares offered pursuant to this prospectus are solely for the accounts of the selling
stockholders.&nbsp;Accordingly, we will not receive any of the proceeds from the sale of the Shares offered by this prospectus.&nbsp;See &#147;Selling Stockholders&#148; and &#147;Plan of Distribution&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also relates to the issuance by us of the shares of common stock issuable upon the exercise of Warrants. We will receive
proceeds from any exercise of the Warrants for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders will pay any underwriting discounts and commissions and
expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the securities. We will bear the costs, fees and expenses incurred in effecting
the registration of the securities covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the Shares to permit the resale of these Shares by the holders thereof from time to time after the date of this prospectus. We will not
receive any of the proceeds from the sale by the selling stockholders of the Shares offered hereby. We will bear all fees and expenses incident to our obligation to register these Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell all or a portion of the Shares held by them and offered hereby from time to time directly or through one or more
underwriters, broker-dealers or agents. If the Shares are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent&#146;s commissions. The Shares may be sold in one
or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block
transactions, pursuant to one or more of the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on any national securities exchange or quotation service on which the shares may be listed or quoted at the time
of sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions otherwise than on these exchanges or systems or in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options, whether such options are listed on an options exchange or
otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales made after the date the Registration Statement is declared effective by the SEC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with a selling stockholder to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may also sell Shares under Rule&nbsp;144 promulgated under the Securities Act, if&nbsp;available, rather than under this prospectus.
In addition, the selling stockholders may transfer the Shares by other means not described in this prospectus. If the selling stockholders effect such transactions by selling Shares to or through underwriters,&nbsp;broker-dealers or agents, such
underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers of the Shares for whom they may act as agent or&nbsp;to whom they may
sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales of the Shares or otherwise,
the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the Shares in the course of hedging in positions they assume. The selling stockholders may also sell shares of common stock
short and deliver Shares covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge Shares to broker-dealers that in turn may sell such
Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may pledge or grant a security interest in some or all of the Shares owned by them
and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule&nbsp;424(b)(3) or other
applicable provision of the Securities Act amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may
transfer and donate the Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required by the Securities Act and the rules and regulations thereunder, the selling stockholders and any broker-dealer participating in the
distribution of Shares may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or
discounts under the Securities Act. At the time a particular offering of the Shares, a prospectus supplement, if required, will be distributed, which will set forth the aggregate amount of Shares being offered and the terms of the offering,
including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling stockholders and any discounts, commissions or concessions allowed or
<FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to broker-dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the securities laws of some states, Shares may be sold in such states
only through registered or licensed brokers or dealers. In addition, in some states Shares offered hereby may not be sold unless such Shares have been registered or qualified for sale in such state or an exemption from registration or qualification
is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling stockholder will sell any or all of the Shares registered pursuant to the
registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and any other person participating in such distribution will be
subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation&nbsp;M of the Exchange Act (&#147;Regulation M&#148;), which may limit the timing of
purchases and sales of any Shares by the selling stockholders and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Shares to engage in market-making
activities with respect to the Shares. All of the foregoing may affect the marketability of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once sold under the registration statement of which this prospectus forms a part, the Shares offered hereby will be freely tradable in the hands of persons
other than our affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_9"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares being offered by the selling stockholders under this prospectus consist of (i)&nbsp;outstanding shares held by certain of the selling stockholders
and (ii)&nbsp;shares issuable to certain of the selling stockholders upon exercise of the Warrants. Pursuant to the Registration Rights Agreement, we have agreed to file a registration statement with the SEC covering the resale of&nbsp;shares of our
capital stock, and this registration statement has been filed pursuant to the Registration Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below lists the selling
stockholders and other information regarding their beneficial ownership (as determined under Section&nbsp;13(d) of the Exchange Act and the rules and regulations thereunder) of our common stock as of December&nbsp;15, 2022. Under Section&nbsp;13(d)
of the Exchange Act, beneficial ownership generally includes voting or investment power with respect to securities, including any securities that grant the holder the right to acquire shares of common stock within 60 days of the date of
determination.&nbsp;These shares are deemed to be outstanding for the purpose of computing the percentage ownership of the person holding those securities, but they are not treated as outstanding for the purpose of computing the percentage ownership
of any other person. The percentage ownership data is based on 17,897,029 shares of our common stock issued and outstanding as of December&nbsp;15, 2022 (as reflected in the records of our stock transfer agent). The Warrants cannot be exercised by a
Warrant holder if, after giving effect thereto, such Warrant holder would beneficially own more than 19.99% of our outstanding common stock. The table below gives effect to this 19.99% beneficial ownership limitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have prepared the table below based on information furnished to us by or on behalf of the selling stockholders. The second column of the table lists the
number of shares of common stock beneficially owned by the selling stockholders as of December&nbsp;15, 2022. The third column of the table lists the Shares being offered under this prospectus by the selling stockholders or by those persons or
entities to whom they transfer, donate, devise, pledge or distribute their Shares or by other successors in interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because, among other things, the
exercise of the Warrants is at the option of the holders, the number of shares of common stock that will actually be issued to the selling stockholders pursuant to the Warrants may be more or less than the number of Shares being offered by this
prospectus. In addition, the Shares may be sold pursuant to this prospectus or in privately negotiated transactions. See &#147;Plan of Distribution.&#148; Because the selling stockholders may sell all, some or none of their Shares in this offering
and because there are currently no agreements, arrangements or undertakings with respect to the sale of any of the Shares, we cannot estimate the number of Shares the selling stockholders will sell under this prospectus. The fourth column of the
table assumes the sale of all of the Shares offered by the selling stockholders pursuant to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for the ownership of the Shares and
Warrants purchased from us in the November 2022 private placement and the entry into the registration right agreement to which this prospectus relates, no selling stockholders have had any material relationship with us within the past three years.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the footnotes below, we believe that the selling stockholders have sole voting
and investment power with respect to all shares of our common stock beneficially owned by them. Since the date on which they provided us with the information below, the selling stockholders may have sold, transferred or otherwise disposed of some or
all of their shares in transactions exempt from the registration requirements of the Securities Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Common Stock<BR>Owned Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum&nbsp;Number&nbsp;of</B><br><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock</B><br><B>to&nbsp;be&nbsp;Sold&nbsp;Pursuant&nbsp;to&nbsp;
this</B><br><B>Prospectus</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Owned After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Selling</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bencich, John<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brio Capital Master Fund Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">699,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">486,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Catalysis Partners, LLC<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">648,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">648,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Clearline Capital
LP<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">768,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">648,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contrarian Achieve SPV LP<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,978,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,978,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dialectic Life Sciences
SPV&nbsp;LLC<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,241,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,241,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Globis Capital Partner, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">543,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lyda Hunt&#151;Herbert Trusts&#151;Barbara Ann
Hunt<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lyda Hunt&#151;Herbert Trusts&#151;Bruce William
Hunt<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lyda Hunt&#151;Herbert Trusts&#151;David Shelton
Hunt<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lyda Hunt&#151;Herbert Trusts&#151;Douglas Herbert Hunt<SUP
STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kingdom Investments, Limited<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MACABA Holdings, LLC<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redcap Investments, LP<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long Focus Capital
Master&nbsp;LTD<SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">464,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walleye Opportunities Master Fund
Ltd<SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">658,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">648,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent of the outstanding shares of our common stock.
</P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 36,920 shares of common stock
and (ii) 11,000 shares of common stock issuable upon exercise of Warrants held by John Bencich. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 535,938 shares of common stock
and (ii) 163,106 shares of common stock issuable upon exercise of Warrants held by Brio Capital Master Fund Ltd. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 432,432 shares of common stock
and (ii) 216,216 shares of common stock issuable upon exercise of Warrants held by Catalysis Partners, LLC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 431,691 shares of common stock
held by Clearline Capital Partners LP (&#147;CCP&#148;), (ii) 120,835 shares of common stock held by Clearline Capital Partners Master Fund LP (&#147;CCPMF&#148;), (iii) 168,937 shares of common stock issuable upon exercise of Warrants held by CCP
and (iv) 47,279 shares of common stock issuable upon exercise of Warrants held by CCPMF. Marc Majzner is a managing member of Clearline Capital LP and shares voting and dispositive power over the shares held by each of CCP and CCPMF.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 1,318,918 shares of common
stock and (ii) 659,459 shares of common stock issuable upon exercise of Warrants held by Contrarian Achieve SPV LLC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 3,494,000 shares of common
stock and (ii) 1,747,000 shares of common stock issuable upon exercise of Warrants held by Dialectic Life Sciences SPV LLC. The number in the column &#147;Percentage (%)&#151;Shares of Common Stock Owned Prior to the Offering&#148; gives effect to
the provision of the Warrants limiting the ability of a Warrant holder to exercise its Warrants if, after giving effect to such exercise, such Warrant holder would beneficially own more than 19.99% of our outstanding common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 435,316 shares of common stock
and (ii) 108,108 shares of common stock issuable upon exercise of Warrants held by Globis Capital Partner, L.P. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 216,216 shares of common stock
and (ii) 108,108 shares of common stock issuable upon exercise of Warrants held by Lyda Hunt&#151;Herbert Trusts&#151;Barbara Ann Hunt. James M. Mason, in his capacity as Trustee, may be deemed to have investment discretion and voting power over the
shares held by Lyda Hunt&#151;Herbert Trusts&#151;Barbara Ann Hunt. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 216,216 shares of common stock
and (ii) 108,108 shares of common stock issuable upon exercise of Warrants held by Lyda Hunt&#151;Herbert Trusts&#151;Bruce William Hunt. James M. Mason, in his capacity as Trustee, may be deemed to have investment discretion and voting power over
the shares held by Lyda Hunt&#151;Herbert Trusts&#151;Bruce William Hunt. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 216,216 shares of common stock
and (ii) 108,108 shares of common stock issuable upon exercise of Warrants held by Lyda Hunt&#151;Herbert Trusts&#151;David Shelton Hunt. James M. Mason, in his capacity as Trustee, may be deemed to have investment discretion and voting power over
the shares held by Lyda Hunt&#151;Herbert Trusts&#151;David Shelton Hunt. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 108,108 shares of common stock
and (ii) 54,054 shares of common stock issuable upon exercise of Warrants held by Lyda Hunt&#151;Herbert Trusts&#151;Douglas Herbert Hunt. James M. Mason, in his capacity as Trustee, may be deemed to have investment discretion and voting power over
the shares held by Lyda Hunt&#151;Herbert Trusts&#151;Douglas Herbert Hunt. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 216,216 shares of common stock
and (ii) 108,108 shares of common stock issuable upon exercise of Warrants held by Kingdom Investments, Limited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 108,108 shares of common stock
and (ii) 54,054 shares of common stock issuable upon exercise of Warrants held by MACABA Holdings, LLC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 216,216 shares of common stock
and (ii) 108,108 shares of common stock issuable upon exercise of Warrants held by Redcap Investments, LP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 356,346 shares of common stock
and (ii) 108,108 shares of common stock issuable upon exercise of Warrants held by Long Focus Capital Master LTD. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock beneficially owned prior to this offering include (i) 432,432 shares of common stock
and (ii) 225,716 shares of common stock issuable upon exercise of Warrants held by Walleye Opportunities Master Fund Ltd. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
entered into the Registration Rights Agreement with the selling stockholders party thereto pursuant to which, among other things, we have provided them with certain registration rights and agreed to pay certain expenses and indemnify them from
certain liabilities in connection with this offering. For more information, see our current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on November&nbsp;18, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP, Seattle, Washington, will issue an opinion about certain legal matters with respect to the securities. Any
underwriters or agents will be advised about legal matters relating to any offering by their own counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc420468_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this prospectus by reference to the Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of
said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g420468g01a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g420468g01a03.jpg
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M 0$! 0$!_\  $0@ <P!H P$1  (1 0,1 ?_$ !\   (" @(# 0
M   *" D&!P$+ @0% __$ #L0  $$ @$# P &"0(& P    0" P4& 0<(  D2
M$1,4%1DA6)?3"A87&!HB(U;2)#@Q,D)5>)66MK?_Q  = 0 !! ,! 0
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MK&;CP^,SV&M1W<7EZ5>_0M1_NRUK,:R1DJ>&CD4-T2Q.%DAE5XI%61&43(X
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M,RV+,J0PQKZL\C!5'/H .>68\*J@LQ !.L-B>*K!+9G<1PP1M+(Y]%1 2?\
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MDF&R")&K.[M7<*J("S,3QV"@$D_<-)Z;@PDCJB9.HSNRHBB4$LS$!5 ^9)(
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MW_T'<72+X:?TY>_R2[_[]/2EOK^B:O\ FE;_ -FUJUON!?[#>;/_ (C\D/\
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MJ]6NU8T]OIW(9C)+$*Y3*-50>U+;#4C9]PW+8&";+%PUL,UQ4Z_KEC6P<?.
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MNV4Z#+Y3>:69&94*R'U_8YJ]PO!>YVPY<O99I-IF).4<:'%65(FZ:N:2B5#
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%2B%?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
